Please login to the form below

Not currently logged in
Email:
Password:

Biotech and vaccines focus for sanofi-aventis

French drugs maker sanofi-aventis has announced that it plans to shift its emphasis to biotechnology and vaccine production

French drugs maker sanofi-aventis (S-A) has announced that by 2014 it plans to shift its emphasis to biotechnology and vaccine production in France, and away from the chemical production of drugs.

The company is presenting employees with its plans to invest €150m in the transfer, which will entail training programmes and the creation of the group's third largest European vaccine production site.

The company said the move reflects its shift in business from producing drugs through synthetic chemistry following patent expirations of several key drugs.

The new activities will create jobs locally, the company said.

31st March 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....
Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....
The power of communication: Engaging diverse groups in healthcare
Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...